Associated tags: Software, Spectrum, Patient, OGM, Biology, Genome, Medicine, SAN, Genomics, Doctor of Philosophy, Research
Locations: SWITZERLAND, MASSACHUSETTS, HAMILTON, NEVADA, LONG, UNITED STATES, UKRAINE, RUSSIA, GEORGIA, SPAIN, LOS ANGELES, RENO, NEW YORK CITY, ISRAEL, SAN DIEGO, CA, US, BEIJING, NEW YORK, CHINA, FLORIDA
Bionano TOUR provides an immersive in-person experience for attendees, combining informative demonstrations of the OGM workflow, the Ionic® system and VIA™ software from internal Bionano experts with presentations from current OGM users who have implemented the workflow for research in hematological malignancies, genetic disease, cell bioprocessing, and other applications.
Key Points:
- Bionano TOUR provides an immersive in-person experience for attendees, combining informative demonstrations of the OGM workflow, the Ionic® system and VIA™ software from internal Bionano experts with presentations from current OGM users who have implemented the workflow for research in hematological malignancies, genetic disease, cell bioprocessing, and other applications.
- "Bionano Symposium, which gathers the global community of OGM users and prospective users in a virtual event that lasts for a week in January, has been enormously successful in showing how the community uses OGM in their research.
- TOUR takes that same level of in-depth OGM experience with users to live, in-person events offering engagement with OGM experts to existing users.
- TOUR also provides the opportunity for new potential OGM users to learn what OGM is all about."
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, Ph.D., Bionano’s president and chief executive officer will present at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023.
Key Points:
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, Ph.D., Bionano’s president and chief executive officer will present at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023.
Hematologic disease,
Workflow,
Genomics,
NGS,
Cancer,
Research,
Doctor of Philosophy,
SAN,
OGM,
VIA,
DSM-IV codes,
Medical imaging,
Retail,
Stratis (configuration daemon) The VIA™ software replaces NxClinical™ software with a completely new platform for visualization, interpretation and reporting for hematologic malignancies across the main data types used in cytogenomics today – OGM, microarray and NGS.
Key Points:
- The VIA™ software replaces NxClinical™ software with a completely new platform for visualization, interpretation and reporting for hematologic malignancies across the main data types used in cytogenomics today – OGM, microarray and NGS.
- VIA further incorporates these data into an intuitive and powerful workflow for hematologic malignancies.
- Bionano’s Stratys system for OGM offers increased throughput capabilities to address the needs of mid and high-volume users.
- “We are pleased to announce two exciting new products that we believe will accelerate adoption of OGM by higher volume users and expand utilization: the Stratys system for OGM and our VIA software with a workflow for hematologic malignancies.
SAN DIEGO, June 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that the company will participate at the Healthcare Virtual Conference , presented by Maxim Group LLC and hosted by M-Vest.
Key Points:
- SAN DIEGO, June 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that the company will participate at the Healthcare Virtual Conference , presented by Maxim Group LLC and hosted by M-Vest.
- Erik Holmlin, Ph.D., Bionano’s president and chief executive officer, is scheduled to present a company overview and fire-side chat discussion hosted by Michael Okunewitch, Senior Research Analyst at Maxim Group on Wednesday, June 21, 2023 at 12:30 pm ET.
Medicine,
FISH,
Augusta University,
National Health Service,
Workflow,
Genomics,
KT,
NGS,
National Comprehensive Cancer Network,
Karyotype,
NCCN,
MDS,
Patient,
SAN,
NHS,
OGM,
Gene,
VIA,
Software,
Medical imaging,
Cancer SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed study from Augusta University on the utility of combining optical genome mapping (OGM) and a 523-gene next-generation sequencing (NGS) panel for the standard evaluation of myeloid cancers.
Key Points:
- SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed study from Augusta University on the utility of combining optical genome mapping (OGM) and a 523-gene next-generation sequencing (NGS) panel for the standard evaluation of myeloid cancers.
- The study describes myeloid cancers as posing a significant challenge to manage, with approximately 50% of cases displaying cytogenetically normal genomes, which can confound traditional analysis approaches.
- In this blinded retrospective analysis of samples from 30 myeloid cancer subjects, the combination of OGM with the 523-gene NGS panel was compared to the common approach of KT and FISH combined with a 54-gene NGS panel.
- A pre-commercial version of Bionano’s new NxClinical™ software enabled analysis of OGM and NGS data together, providing an integrated picture of genomic variation.
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today.
Key Points:
- SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today.
- The final voting results will be available in a current report on Form 8-K, which will be filed with the SEC within 4 days of the meeting.
- “We appreciate the support of our stockholders on these critically important proxy proposals,” said Erik Holmlin, Ph.D., president and chief executive officer of Bionano.
- “We now look forward to continuing to execute upon our strategy.”
ISSCR,
Genomics,
National Institutes of Health,
Research,
Immortalised cell line,
Regenerative medicine,
SAN,
International Society for Stem Cell Research,
OGM,
NIH,
International Society,
Safety,
Medical device ISSCR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in stem cell research and regenerative medicine.
Key Points:
- ISSCR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in stem cell research and regenerative medicine.
- The ISSCR conference will be held June 14-17, 2023, online and in-person in Boston, Massachusetts.
- Presentations will cover OGM’s utility for monitoring genomic integrity and off-target effects in cell lines and its potential to improve the quality, safety, and overall risk profile of next-generation therapy development and manufacturing.
- A scientific poster by Dr. Andy Pang from Bionano, covering the use of OGM in cell manufacturing and bioprocessing applications, will be on display during the conference.
Hospital for Sick Children,
Lymphoma,
Duke University,
Research Triangle,
Central nervous system,
ALL,
Acute lymphoblastic leukemia,
Cutaneous T-cell lymphoma,
Stanford University,
CTCL,
Genomics,
Pathology,
Cancer,
SVS,
Prognosis,
Research,
Infection,
Biomarker,
Doctor of Philosophy,
CNS,
Creativity,
Drug resistance,
Patient,
The Hospital,
SAN,
Neoplasm,
Hospital,
Health,
OGM,
DSM-IV codes,
Bone marrow,
Medical imaging,
Vaccine,
Pharmaceutical industry Additionally, 12 other winners from around the world have been awarded complimentary OGM services from Bionano Laboratories.
Key Points:
- Additionally, 12 other winners from around the world have been awarded complimentary OGM services from Bionano Laboratories.
- Bionano’s Innovator Research program was established to fuel novel research using the company’s OGM products to detect relevant structural variants (SVs), demonstrating OGM’s potential to advance discoveries and innovation in ways that may elevate health and wellness for all people.
- The Bionano Innovator Research Grant will enable us to resolve structural variants as they arise during treatment and to determine their role in drug resistance.
- The Bionano Innovator Research Grant program was established to attract applicants with projects that demonstrate exemplary vision and creativity in leveraging OGM and genomic technologies to tackle complex challenges.
Immortalised cell line,
Cell,
MH,
Genetics,
Acute lymphoblastic leukemia,
Ibis,
Cancer,
Research,
DSM-IV codes,
CHU,
Gene editing,
Radbod,
UZ Leuven,
EHA,
European Central Bank,
OGM,
Bone marrow,
Medical device,
Online shopping Scientific posters from Dr. Jose Garcia Martinez (Hospital Infantil Universitario Niño Jesús) and Dr. Jonathan Lühmann (MH Hannover) will cover OGM’s use in pediatric acute lymphoblastic leukemia research.
Key Points:
- Scientific posters from Dr. Jose Garcia Martinez (Hospital Infantil Universitario Niño Jesús) and Dr. Jonathan Lühmann (MH Hannover) will cover OGM’s use in pediatric acute lymphoblastic leukemia research.
- “Researchers and scientists continue to push forward cutting-edge research in the human genetics space, and we are pleased to see them share their findings with conference attendees.
- These presentations point to the continued expansion of OGM into clinical research applications for cancer, genetic disease and cell therapy where we believe OGM has the potential to deliver significant advantages relative to the current methodologies.”
For more information on EHA, please visit https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/ .
- For more information on ESHG, please visit https://bionano.com/eshg2023/ .
Tissue,
DNA,
G2,
HRD,
Genomics,
NGS,
ITP,
RNA,
Doctor of Philosophy,
Isotachophoresis,
Chemistry,
Dicarboxylic acid,
SAN,
UHMW,
OGM,
Ionic,
Phosphorus SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the commercial release of new kits for its Ionic® Purification System featuring new chemistry for nucleic acid extraction from formalin-fixed paraffin-embedded (FFPE) and tumor tissue.
Key Points:
- SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the commercial release of new kits for its Ionic® Purification System featuring new chemistry for nucleic acid extraction from formalin-fixed paraffin-embedded (FFPE) and tumor tissue.
- Most clinical samples used in oncology research are stored as FFPE tissues, which often contain degraded or fragmented nucleic acid.
- Conventional extraction methods are labor intensive and can further damage nucleic acid during the extraction and purification process.
- The Ionic® G2 chemistry includes four new kits for use with the Ionic Purification System, including G2 FFPE to DNA, G2 FFPE to RNA, G2 FFPE Complete and G2 Tissue to DNA.
